Search Results
Results found for "Domain Therapeutics"
- Chemical Probes for GPCR Imaging and Internalization with Dr. Johannes Broichhagen | Dr. GPCR Ecosystem
The moment when super-resolution imaging revealed nanoscale receptor domains that conventional tools
- Started in medicinal chemistry. Got hooked on ligand design. Dr. Maria Majellaro didn’t plan to run a biotech company. A thesis project, a mentor’s advice, and a leap during the pandemic changed everything. Now she’s leading Celtarys, building custom fluorescent probes, and partnering with Dr. GPCR to support assay development worldwide. Meet Celtarys and learn more about its leading work on ligand-linker-fluorophore chemistry 🚀 ✳️ Listen now: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-168-with-dr.-maria-majellaro-from-celtarys #GPCRcommunity #DrGPCR #FluorescentLigands #GPCRdrugDiscovery #ScientificLeadership #BiotechInnovation | Dr. GPCR Ecosystem
Early hiring decisions are usually made around skills, experience, and domain expertise.
- Dr. Khaled Abdelrahman, Victoria Rasmussen and Madelyn Moore | Dr. GPCR Ecosystem
He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics of GPCRs in disease states to help test the feasibility of using protein-targeted degradation as a therapeutic Maddi is currently a second year Ph.D. student in the Molecular Pharmacology and Therapeutics (MPaT)
- Dr. Juan José Fung | Dr. GPCR Ecosystem
Juan José Fung is a Principal Scientist at GPCR Therapeutics, Inc , a drug discovery company focused Juan José Fung on the web LinkedIn GPCR Therapeutics Dr. GPCR Ecosystem Enjoying the Dr.
- ep 175 with jens carlsson clip 1 | Dr. GPCR Ecosystem
Early hiring decisions are usually made around skills, experience, and domain expertise.
- Dr. Khaled Abdelrahman | Dr. GPCR Ecosystem
He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics
- Leadership, Impact, and GPCR Signaling with Dr. Michelle Halls | Dr. GPCR Ecosystem
Michelle Halls reveals how organized GPCR signaling drives assay innovation and new therapeutic insights concentrations, her work highlights why receptor localization and protein complex assembly matter for therapeutic localized signaling events, how these mechanisms are hijacked in disease, and how they can be leveraged for therapeutic
- Dr. Samuel Hoare | Dr. GPCR Ecosystem
company supporting pharmaceutical, life science, and academic scientists in the development of new therapeutics analysis of drug action and is known for applying binding kinetics to the development of effective therapeutics
- University | Dr. GPCR Ecosystem
created by scientists, for scientists—bringing the global GPCR community together to advance biology and therapeutics Explore 200+ expert talks that bring GPCR discoveries to life From structural biology to therapeutics players in GPCR pharmacology and learn how agonists and antagonists shape efficacy, signaling, and therapeutic orthosteric drugs and uncover the power of allosteric modulators and kinetic insights to unlock new therapeutic Take the Next Step You're building the future of GPCR therapeutics.
- Courses (All) - Premium | Dr. GPCR Ecosystem
Measuring and understanding bias helps design drugs that maximize therapeutic benefits while minimizing See- The Importance of Pharmacologic Assays Lecture 2: Drug Disposition in Physiological Tissues as a Therapeutic Lecture 4: Unconventional GPCR Ligands as Drugs Lecture 5: Unique Exploitable GPCR-Ligand Behaviors for Therapeutic
- Dr. Katarina Nemec | Dr. GPCR Ecosystem
I aim to discover new therapeutic approaches, and druggable molecules or refine canonical drug targets while performing various cell-based experiments to understand the binding, activation, and signaling of therapeutically
- Dr. Rosie Dawaliby | Dr. GPCR Ecosystem
In 2016, I joined a company that specialized in therapeutic candidate discovery targeting GPCR ( Confo Therapeutics ) as a team and project leader for antibody discovery for metabolic and inflammatory diseases
- Dr. Stephane Angers | Dr. GPCR Ecosystem
He is the scientific founder of two biotech companies, ModMab Therapeutics , and AntlerA Therapeutics
- From Curiosity to Breakthrough: Ajay Yekkirala on GPCR Innovation | Dr. GPCR Ecosystem
Biotech founder Ajay Yekkirala shares how AI, GPCRs, and bold questions are driving next-gen pain therapeutics rerouted his path toward a breakthrough GPCR research career The inside story behind founding Blue Therapeutics Driven by the opioid crisis and the lack of non-addictive pain treatments, Ajay co-founded Blue Therapeutics
- Eurofins DiscoverX | Dr. GPCR | Dr. GPCR Ecosystem
Your One-Stop-Shop for GPCR Drug Discovery and Development Researchers developing GPCR-targeted therapeutics 25+ years of expertise and provides you with cell-based assay solutions for basic research through therapeutic Principle of Eurofins DiscoverX Cell-based Assays Whether you are developing small-molecule or biologic therapeutic Product Solutions for more information on GPCR cell-based solutions for basic research, discovery, and therapeutic
- A Brief History of allosteric modulation with Dr. Arthur Christopoulos | Dr. GPCR Ecosystem
Award and the Goodman and Gilman Award from the American Society for Pharmacology and Experimental Therapeutics They explored the evolution of the field, allosteric modulation concepts, and potential therapeutic approaches Arthur will work on designing ligands for specific receptors, aiming to create biased agonists for therapeutic Yamina discussed the potential of autoantibodies and allosteric modulation in the context of disease and therapeutic endogenous allosteric ligands and the possibility of using a neutral allosteric ligand as a preferred therapeutic
- Dr. GPCR Team | Dr. GPCR Ecosystem
During that time, I investigated the effect of lung cancer-related mutations in the GAIN domain of the
- Dr. Stuart Maudsley | Dr. GPCR Ecosystem
At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics
- Dr. Stuart Maudsley | Dr. GPCR Ecosystem
At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics
- Dr. Stuart Maudsley | Dr. GPCR Ecosystem
At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics
- Signals, pH, and Discovery : Cracking GPCR Mysteries with Dr. Ian Chronis | Dr. GPCR Ecosystem
Yamina underscores the therapeutic potential of GPR65, especially in the context of cancer immunotherapy , and how understanding receptor activity in acidic microenvironments could unlock new therapeutic strategies
- GPCR Pharmacology, Career Twists & Serendipity with Sokhom Pin | Dr. GPCR Ecosystem
From his early work as a technician at Johns Hopkins Hospital to leading biology at Servo Therapeutics years of drug discovery research in the pharmaceutical industry, where he works mainly on GPCRs as therapeutic He is passionate about mechanistic profiling of therapeutic molecules as well as drug discovery in general
- Dr. Lauren M. Slosky | Dr. GPCR Ecosystem
protein-coupled receptors (GPCRs) regulate motivated behavior and how these receptors can be targeted for therapeutic distinct signaling pathways with their physiological effects and may serve as the basis for more selective therapeutics
- Trademark Policy | Dr. GPCR Ecosystem
restriction is prohibited by applicable law), and you agree not to register or attempt to register any domain For example, you may not use our marks: In domain names As app icons or featured in an app As the most
- Yao Lu (Jackie) | Dr. GPCR Ecosystem
molecular explanation of small molecules for their pre-clinical efficacy and to support the design of novel therapeutics
- Dr. Terry Hébert | Dr. GPCR Ecosystem
Terry Hébert is a Professor within the Department of Pharmacology & Therapeutics at McGill University
- Tanishka S. Saraf | Dr. GPCR Ecosystem
Saraf " My research focuses on evaluating and targeting serotonin 1A receptors for therapeutic outcomes
- Dr. Aurélien Rizk | Dr. GPCR Ecosystem
the company's ability to predict the residence time of a ligand and its potential correlation with a therapeutic Therapeutic Effect and Receptor Interactions Aurelien Rizk and Yamina had a detailed discussion about the importance of gaining more information about the therapeutic effect in patients or animals and the They also shared their preference for small molecule therapies over protein therapeutics.
- Lighting up a native pancreatic islet isn’t just a technical win it’s a shift in what GPCR imaging can reveal | Dr. GPCR Ecosystem
This is the kind of advance that matters for anyone building tools, assays, or therapeutics around receptor
- irreversible drugs post 3 | Dr. GPCR Ecosystem
lesson: Target depletion vs. replenishment dynamics — how offset rates control exposure windows, shape therapeutic























